Health systems are placing increasing emphasis on improving the design and operation of clinical trials, with a view to increasing the rate of innovation and adoption of health technologies in a ‘value-based’ world. We present a value-based, Bayesian decision-theoretic model of a two-armed clinical trial and health technology adoption decision in which the recruitment rate and duration of the recruitment period are optimised. We account for a wide range of regulatory and practical contexts, addressing questions of how health is valued (considering discounting, the horizon of an adoption decision, and the endogenisation of outcomes for patients in the trial), and the state of clinical practice prior to commencement of the trial (we consider both exploratory trials for pharmaceutical research and pragmatic trials which compare technologies currently in use). We apply the model using research and treatment cost data from an existing trial and health technology assessment and challenge traditional perceptions concerning the efficiency, length and knowledge that may be gained from clinical research when trial teams are charged with delivering ‘value’ efficiently.

Andres Alban, S.C. (2020). Value-based clinical trials: selecting trial lengths and recruitment rates in different regulatory contexts. York : Department of Economics, University of York.

Value-based clinical trials: selecting trial lengths and recruitment rates in different regulatory contexts

Martin Forster
Ultimo
2020

Abstract

Health systems are placing increasing emphasis on improving the design and operation of clinical trials, with a view to increasing the rate of innovation and adoption of health technologies in a ‘value-based’ world. We present a value-based, Bayesian decision-theoretic model of a two-armed clinical trial and health technology adoption decision in which the recruitment rate and duration of the recruitment period are optimised. We account for a wide range of regulatory and practical contexts, addressing questions of how health is valued (considering discounting, the horizon of an adoption decision, and the endogenisation of outcomes for patients in the trial), and the state of clinical practice prior to commencement of the trial (we consider both exploratory trials for pharmaceutical research and pragmatic trials which compare technologies currently in use). We apply the model using research and treatment cost data from an existing trial and health technology assessment and challenge traditional perceptions concerning the efficiency, length and knowledge that may be gained from clinical research when trial teams are charged with delivering ‘value’ efficiently.
2020
51
Andres Alban, S.C. (2020). Value-based clinical trials: selecting trial lengths and recruitment rates in different regulatory contexts. York : Department of Economics, University of York.
Andres Alban, Stephen Chick, Martin Forster
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/810188
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact